Corrine Savill - 18 Feb 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Role
Chief Business Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 17:00:06 UTC
Previous filing
21 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Savill Corrine Chief Business Officer C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE /s/ Jacquelyn Sumer, Attorney-in-Fact 19 Feb 2026 0001837524

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 18 Feb 2026 Common Stock 175,000 $12.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.